Objectives: It has been known for almost a century that amyloidosis is frequently associated with chronic bacterial infection. Islet amyloid deposit is characteristic of type 2 diabetes. Periodontal disease, which is predominantly caused by several Gram negative bacteria, is a risk factor for type 2 diabetes. The goal of the study was to explore whether bacteria or their toxic components may play a role in type 2 diabetes.
INTRODUCTION
Type 2 diabetes, non insulin dependent diabetes mellitus (NIDDM), or adult-onset diabetes, is characterized by the progressive degeneration of islet -cells of the pancreas resulting in a fall of insulin secretion and decreased insulin action on peripheral tissues. In type 2 diabetes, there is an accumulation of amylin, a 37-amino acid islet amyloid polypeptide (IAPP), in the affected Langerhans islets. It is derived from proamylin, a 67-amino acid precursor protein [1] [2] [3] . Amylin is produced and secreted, along with insulin, by islet -cells. It is related to the calcitonin/calcitonin generelated peptide family, and is involved in homeostatic maintenance [4] . The cause of diabetes type 2 and the mechanisms involved in amyloid formation are not yet known. [5] [6] [7] [8] [9] and treatment of periodontal infections in diabetics improves glycemic control [6] [7] [8] [9] .
It has been known for almost a century that amyloidosis is frequently associated with chronic bacterial infections [10, 11] . Lipopolysaccharide (LPS), the toxic product of Gram negative bacteria and bacterial peptidoglycan (BPG), the building block of the cell wall of virtually all prokaryotes, have long been used as models of experimental amyloidosis. LPS and BPG are powerful inflammatory stimulators and are amyloidogenic [10] . Seroprevalence of Chlamydia (Chlamydophila) pneumoniae (C. pneumoniae) m [12] and Helicobacter pylori (H. pylori) [13] [14] [15] and a significantly high percentage of fluorescent treponemal antibody reaction [16] were observed in diabetic patients compared to controls. The question is raised as to whether bacteria or their toxic products may be involved in type 2 diabetes.
Since bacteria, LPS and BPG are powerful inflammatory stimulators and because inflammation plays an important role in the pathogenesis of several age related degenerative disorders, (e.g. Alzheimer's disease) [17] , we expected that local inflammatory processes may also be present in the pancreas in type 2 diabetes.
Accordingly, the present study was undertaken to analyze whether LPS, BPG and local inflammatory processes are present in association with islet amyloid deposits in 10 patients with type 2 diabetes compared to 12 aged matched controls. Immunohistochemical detection of specific C. pneumonae and H. pylori antigens was also performed.
MATERIAL & METHODS

Autopsy Cases Investigated
Pancreatic tissue from 22 autopsy cases was analyzed ( Table 1 ). The series included 10 patients with clinically diagnosed type 2 diabetes (Average age: 73, 9 -range 66-78), including one patient with associated pancreatic cancer (Case 9. Table 1 ) and 12 age matched controls (Average age: 71, 7 -range 54-86). No diabetes was clinically recorded and no pathological changes were observed by routine pathological examination in the pancreas in the 12 control cases.
In each case samples about 2 x 1 x 0.5 cm large were removed from the pancreas. One was embedded in paraffin and another was frozen in liquid N 2 and stored at -80°C until processing. Paraffin sections (7μm) were used for the histochemical analysis and frozen sections (7 or 20μm) for both, the histochemical and immunohistochemical analyses. The frozen sections, depending on the antibody utilized, were postfixed with 4% paraformaldehyde for 10 minutes at room temperature or in acetone for 2-10 min at 4ºC.
Histochemical and Immunohistochemical Analyses
Paraffin embedded and 4% paraformaldehyde fixed frozen sections of the pancreas were stained by haematoxylin and eosin (H&E). Thioflavin S and Congo red techniques were used to detect islet amyloid deposits.
The types and dilutions of antibodies used are detailed in Table 2 . Two polyclonal rabbit antibodies, one raised against human IAPP 1-37 (Hammersmith, kind gift of Dr. A Clark) and one against rat amylin (Peninsula Laboratories, RGG7323, kind gift of Dr. Bruce Verchere) as well as a monoclonal antibody (clone R10/11, Serotec) raised against a synthetic peptide sequence within IAPP, were used to detect amylin. The sequences recognized by the polyclonal antibodies were verified using membrane arrays of robotically synthesized overlapping peptides [18] covering the amylin sequence. The "Hammersmith" antibody strongly recognized the sequence NFGAILSSTN (amino acids 22-31) of amylin. The RGG-7323 strongly recognized the sequence QRLANFLVHS (amino acids 10-19) which differs from the rat only in the H to R of position 18 (not shown). The monoclonal antibody R10/99 is reported by the supplier to recognize an epitope defined by amino acids 29-37.
An extended immunohistochemical analysis was performed using a panel of antibodies to detect LPS, BPG and cellular and humoral immune responses in the pancreas. Two monoclonal and a polyclonal antibody against LPS were utilized. One monoclonal antibody (J5) was raised against the inner core of LPS and the other against lipid A which are highly conserved in Gram negative bacteria. The polyclonal rabbit antibody was made against purified LPS from E. coli (Biodesign B30506R) which cross-react with the LPS of other Gram negative bacteria. Immunostaining with the J5 and the polyclonal anti-LPS antibodies was performed on unfixed frozen sections mounted on slides. Immunostaining with the anti-Lipid-A antibody was performed on frozen sections fixed in acetone for 2 min at 4ºC and treated with 0.1% amylase for 3 minutes at 37ºC. BPG was detected as previously described [19] .
Immunohistochermical detection of specific C. pneumoniae and H. pylori antigens using pancreas sections fixed with 4% paraformaldehyde for 5 minutes was also performed in six diabetic and three control cases (Cases 3, 4-6, 8, 9 and 11, 12, 22, Table 1 ). For the detection of C. pneumoniae, two species specific monoclonal antibodies (clone RR402 (M 6600, Dako Cytomation [20, 21] and clone 57/062, 1984-9038, Biogenesis), which do not cross-react with other Chlamydia species and a polyclonal, genus specific antibody (B47829R, Biodesign) which recognizes C. pneumoniae, C. trachomatis and C. psittaci were used. For the detection of H. pylori a polyclonal antibody was employed, which was known for its specificity and sensitivity to detect H. pylori in infected tissues in gastritis and gastric cancers [22] [23] [24] .
Anti-human-HLA-DR (Clone C3/43) and anti-C3bi (CD11b or Mac-1, DakoCytomation, M0741) antibody, which recognizes inflammatory cells expressing complement receptor 3 (CR3), were used to detect activated macrophages. Antibodies to sensitive markers of B (CD 20) and T (CD4, CD8) lymphocytes were used to study cellular immune responses and antibodies to the human complement components C3d, C4d, and the membrane attack complex C5b-9 (DAKO, M0777) were used to detect complement activation.
For immunostaining, the avidin-biotin-peroxidase technique was used as described previously in detail [25] . Smears of cultured Escherichia coli and acetone fixed frozen sections of the tonsil of an aged patient, known to contain Gram negative bacteria as part of the oral flora, were used as positive controls for the detection of LPS and BPG. Sections immunostained with normal serum alone were used as controls. To analyze whether LPS, BPG and islet amylin deposits are localized in the same areas of the diabetic pancreas, serial sections spaced 7-14μm apart were immunostained with anti-LPS, anti-BPG and anti-amylin antibodies, respectively. Double immunofluorescent staining to detect overlapping expression of LPS and amylin was also carried out with fluorescence-tagged secondary antibodies as previously described [25] . For this purpose, pancreatic sections with islet amyloid deposits were incubated with a mixture of a polyclonal anti-human amylin (Hammersmith, dil. 1:200) and a monoclonal anti-core LPS J5 antibody (Dil 1:100). A combination of monoclonal anti-amylin (GTX 74673, GeneTex) and rabbit anti-LPS (B30506R, Biodesign) antibodies was also used.
To analyze whether HLA-DR positive macrophages are also associated with islet amyloid deposits pancreas sections of diabetic patients were doubly immunostained using monoclonal anti-HLA-DR (DakoCytomation, Carpinteria, CA, dil. 1:100) and polyclonal anti-amylin (a.a. Semiquantitative analysis of amylin, bacterial antigens, inflammatory markers, including complement components C3d, C4d and C5b-9 ( Table 1 ) was performed in all cases. It was based on the severity of the immunoreaction observed in the Langerhans islets and was entered in four grades: absence of immunoreaction -; mild +; moderate ++; and severe +++ immunoreaction.
Immunoabsorbtion Assay
Immunoabsorption was used to further test the specificities of the LPS and BPG antibodies. For the anti-LPS antibodies, commercially available purified E. coli Serotype 055-B5 LPS (Sigma, L-4524) was used as the antigen. To 50 g of purified LPS, 500 l TRIS and 2.5 l anti-LPS antibody (anti-core LPS J5 or polyclonal anti-LPS) were added. In parallel, the same amount of anti-LPS antibody was diluted in 500 l of TRIS. Following overnight rotation of these samples at 4°C, they were centrifuged at 2300 rpm for 20 minutes. Following filtration (0.2 m Millipore filter) the supernatants were used for immunostaining of pancreatic sections of patients with type 2 diabetes. Immunoabsorbtion for the anti-BPG antibodies was performed as previously reported [19] . (Fig. 1A outlined  with arrows) were not easy to recognize on H&E-stained sections in patients with type 2 diabetes, particularly in cases with less severe alterations. However, they were easily detected by thioflavin S (Fig. 1B) and Congo red (not shown) staining as well as by their amylin immunoreactivity (Fig.  1C) . Such islet amyloid deposits were found in the pancreas in all 10 diabetic cases. Islet amyloid deposits of a lesser degree were observed in three of the control cases but were totally absent in the other 9 controls ( Table 1) . On immunostained sections where the use of primary antibody was omitted were negative (not shown).
RESULTS
Amyloid deposits in Langerhans islets
A positive immunoreaction in the affected Langerhans islets was obtained with all 3 anti-LPS antibodies (Fig. 1D-F ) as well as with the anti-BPG antibody (Fig. 1G) . Control pancreatic sections, except for the 3 cases with minor amyloid deposits, gave negative staining of the pancreatic islets with LPS (Fig. 1H) and BPG (Fig. 1I) .
On serial sections which were immunostained for LPS, BPG and amylin, respectively, LPS, BPG and amylin were all localized in the affected areas of the pancreatic islets. Localization of amylin and LPS in the same areas of the affected islet of a diabetic patient is illustrated in Fig. (1J-K) , where a pancreatic section was doubly stained using immunofluorescence with the monoclonal anti-core LPS J5 antibody and the polyclonal anti-amylin (Hammersmith) antibodies. The use of TRITC tagged secondary antibody for the anti-core LPS J5 antibody produced a red LPS fluorescence (Fig. 1J) and the FITC tagged secondary antibody for the polyclonal anti-amylin antibody produced a green fluorescence for amylin (Fig. 1K) . The orange color on the merged images in Fig. (1L) indicates the overlap of LPS and amylin.
At high magnification at the periphery of homogenous islet amyloid deposits, helically shaped (0.1-0.3 x 10-40 m) coiled filaments (e.g. Fig. 2A,C) , sometimes forming rings or globular structures ( Fig. 2A, asterisk) as well as, coccoid forms of about 1 m in diameter (Fig. 2B,D) , sometimes forming pairs, could be observed. These were seen on thioflavin S-stained and on LPS-and BPG-immunostained sections. LPS positive round or granular structures (0.3-2 m in diameter) accumulating intracellularly (Fig. 2E) were also observed. In some cases accumulation of LPS and BPG positive structures reminiscent of bacteria were also seen along the pancreatic septae. These helically shaped filamentous (Fig. 2F,G) and small coccoid structures (Fig. 2H) reminiscent of various forms of bacteria were also immunoreactive for C5b9, the membrane attack complex which assembles only on viable cell membranes. Fig. (2I) illustrates bacterial structures recognized by anti-core LPS J5 antibody in the tonsil of an aged patient known to be the site of accumulation of Gram negative bacteria and which was used as positive control. Positive C. pneumoniae immunoreaction was observed in the affected Langerhans islet (Fig. 3A-C) in 5 of the 6 diabetic cases analyzed (Cases 3, 5, 6, 8, 9 of Table 1 ). H. pylori were detected in the pancreatic islets (Fig. 3E-G ) of 4 patients with type 2 diabetes (Cases 3, 5, 8, 9 of Table  1 ). In three diabetic cases C. pneumoniae and H. pylori were both detected in pancreatic islets (Cases 5, 8, 9 of Table 1 ). C. pneumoniae was detected intracellularly as a less or more dense granular intracytoplasmic staining (Fig. 3B,C) . Similar C. pneumoniae immunoreaction was also seen in atherosclerotic lesions of small sized pancreatic arteries in some diabetic cases (not shown here). On pancreas sections doubly immunostained with HLA-DR and C. pneumoniae antibodies, overlapping expression of HLA-DR activated macrophages and the intracellular pathogen C. pneumoniae was observed (not shown here).
H. pylori immunostaining appeared as slightly curved rod like (0.5-1 x 2-7 m) bacillary structures (Fig. 3F,G) observed extracellularly. Pancreas sections of the two control cases without islet amyloid deposit (Cases 11 and 12, Table 1 ) were negative for C. pneumoniae and H. pylori (Fig. 3D  and 3H, respectively) . In the third control case with clinically silent islet amyloid deposit C. pneumoniae and H. pylori were both detected (Case 22, Table 1 ). The immunoreaction for both was mild when compared to that of the diabetic cases. Control sections where immunostaining was performed with the omission of the primary antibody were negative (not shown). A strong inflammatory response was associated with amyloid deposits in the diabetic cases (Fig. 4) . Clumps of HLA-DR (Fig. 4A) and C3bi (Fig. 4B) immunoreactive cells surrounded islet amyloid deposits but were absent in control pancreas (Fig. 4C) . Only a few CD20 immunoreactive B cells were observed in the diabetic pancreas (Fig. 4D) along with modestly increased numbers of CD 4 (Fig. 4E) immunoreactive cells. The number of the CD 8 (Fig. 4F) positive lymphocytes (Fig. 2G) was the highest. Only scattered CD 20, CD 4, or CD8 positive lymphocytes, sometimes in relation to blood vessels, were seen in the controls (Fig. 4G) .
Abundant immunoreactivity to activated complement proteins was clearly observed in the pancreas of all diabetic cases. This is illustrated for C3d (Fig. 4H), C4d (Fig. 4I) and C5b-9 (Fig. 4J) . Such immunoreactivity was associated with islet amyloid deposits, and in some cases was also seen along the loose connective tissue of fine pancreatic septae. Focal HLA-DR positive activated macrophages and C3d, C4d and C5b-9 immunoreactivities were also associated with atherosclerotic lesions of pancreatic arteries observed in some diabetic cases. Immunoreactivity for complement proteins was not observed in the Langerhans islets of control cases (Fig. 4K ) except in one (Case 22, Table 1 ) with mild clinically silent amyloid deposits. On doubly immunostained sections amyloid deposition and inflammatory reactions, complement activation (e.g. amylin and HLA-DR illustrated in Fig. (4L-N) ) overlapped in affected areas of the Langerhans Islets.
DISCUSSION
Type 2 diabetes, which accounts for 90-95% of all diabetic cases, has become a major health concern [26] . Using anti-LPS and anti-BPG antibodies, we demonstrated the presence of these two bacterial toxic components in the affected Langerhans islets of all type 2 diabetic cases analyzed. On doubly immunostained pancreatic sections, LPS and BPG were co-localized with amylin. Amyloid deposit, LPS and BPG immunoreactivity of a mild degree was also observed in the pancreas in three control cases. It is possible that they corresponded to early, subclinical cases of type 2 diabetes. Bacteria, or their toxic products, would be expected to initiate a local inflammatory reaction; however the occurrence of local inflammation in type 2 diabetes is not established. We observed clumps of HLA-DR and C3bi positive macrophages around islet amyloid deposits. Such cells are designed to clean foreign cells such as bacteria and damaged host cells and debris, including extracellular amyloid deposits. Abundant immunoreactivity to the activated complement proteins C3d, C4d and C5b-9 was also present, clearly showing that the classical complement pathway is fully activated in type 2 diabetes. Such results are similar to those observed in Alzheimer's disease [27] [28] [29] . These results indicate that local immune responses are involved in the pathogenesis of type 2 diabetes, which would not be surprising, given the presence of LPS a known activator of the macrophage receptor CD14 [30] . Despite the apparent lack of lymphocytic infiltrates on H&E stained sections of the pancreas in 8 of the 10 type 2 diabetic cases, using sensitive immuno-markers of B and T lymphocytes, increased number of CD4, and particularly of CD 8 positive T cells, were present compared to controls indicating the possibility of a minimal involvement of the adaptive immune system.
The presence of LPS and BPG and observance of C5b-9 positive structures morphologically compatible with bacteria suggest that chronic bacterial infection may be involved in type 2 diabetes. The membrane attack complex only assembles on viable cell membranes eliminating the possibility that C5b-9 immunoreactive bacterial structures may correspond to post mortem bacterial growth. Intracellular C. pneumoniae was observed in the affected islets in 5 of the 6 diabetic cases analyzed and extracellularly located slightly coiled H. pylori immunoreactive bacteria were also seen in the affected Langerhans islets in 4 diabetic cases. Simultaneous occurrence of C. pneumoniae and H. pylori antigens was observed in 3 cases. These results suggest that C. pneumoniae and H. pylori may be candidate pathogens for type 2 diabetes. Chronic periodontitis is a known risk factor for type 2 diabetes [5] [6] [7] [8] [9] 31] and the periodontal pathogen T. denticola predominated in chronic periodontal lesions of patients with type 2 diabetes compared to controls [31] . We have observed LPS, BPG and C5b-9 positive helically shaped bacteria morphologically identical to vegetative and atypical forms of spirochetes in several diabetic patients suggesting that spirochetes (including oral and intestinal spirochetes) may also be candidate pathogens for type 2 diabetes. The present results are in harmony with classical observation that the onset of diabetes may occur during or after an acute infection and that the occurrence of diabetes in chronic bacterial infections like tuberculosis, leprosy and syphilis is repeatedly documented.
C. pneumonia [32] [33] [34] [35] , H. pylori [36] [37] [38] and periodontal pathogens, including T. denticola [39] [40] and virus infection are also linked to cardiovascular disorders including atherosclerosis indicating that these infectious agents, via haematogen dissemination, may reach and infect various organs distant from the primary site of infection. Some intestinal pathogens (e.g. H. pylori) may also reach the pancreas directly from the gastrointestinal tract. The simultaneous occurrence of C. pneumoniae and H. pylori and the various types of LPS and BPG positive (coccoid, rod, helically shaped or fusiform) organisms in pancreatic islets of the same diabetic patient suggest that similarly to periodontitis and atherosclerosis concurrent infection by several pathogens may also occur in type 2 diabetes. Improvement of glycemic control was observed after eradication of H. pylori infection in diabetic patients which further suggests that early antibiotic and anti-inflammatory treatment may be efficient to prevent or slow down the disease process [41] . That pathogens may evade host defenses and establish chronic or latent infection has received little attention in the past. The outcome of infection is determined by the genetic predisposition of the patient [42, 43] and by the virulence and biology of the infecting agent. Environmental factors and nutrition are key determinants of disease expression as well. Bacteria are powerful stimulators of inflammation and are amyloidogenic.
The present results suggest that type 2 diabetes may be caused by inflammatory processes in the pancreas, initiated by invading pathogens or their persisting toxic components (e.g. LPS and BPG) and involving innate and possibly even adaptive immune responses. In the affected pancreas the pathogenic bacteria and/or their toxic components can be observed, along with a host immunological response. The response itself appears to be characteristic of a localized inflammatory process associated with the sites of tissue damage, similar to that e.g. seen in Alzheimer's disease [44] [45] [46] [47] .
Careful prospective studies are needed. In addition to diagnostic serological tests, and an attempt to cultivate bacteria from the pancreas, in parallel, the detection of specific antigens and genes (e.g. PCR, in situ hybridization) in pancreas of patients with type-2 diabetes should be done.
In conclusion, the present results indicate that local inflammatory processes and the bacterial toxic components LPS and BPG are present in the affected Langerhans islets in patients with type 2 diabetes. The results also suggest that bacteria or their slowly degradable components may initiate and sustain chronic inflammation and lead to islet amyloid deposits in type 2 diabetes. They also indicate that the classical complement pathway is activated in type 2 diabetes. Further investigations will be necessary and are important as they may open new avenues for the prevention of this age related chronic disorder. So far, approaches to treatment of type 2 diabetes have largely been directed at limiting the demand for insulin, it may be possible to devise methods for protecting the islet cells themselves, by reducing inflammation and preventing infection.
